LT3601283T - Kondensuoto imidazo-piperidino jak inhibitoriaus junginys - Google Patents

Kondensuoto imidazo-piperidino jak inhibitoriaus junginys

Info

Publication number
LT3601283T
LT3601283T LTEPPCT/US2018/030148T LT18030148T LT3601283T LT 3601283 T LT3601283 T LT 3601283T LT 18030148 T LT18030148 T LT 18030148T LT 3601283 T LT3601283 T LT 3601283T
Authority
LT
Lithuania
Prior art keywords
inhibitor compound
jak inhibitor
piperidine
fused imidazo
imidazo
Prior art date
Application number
LTEPPCT/US2018/030148T
Other languages
English (en)
Inventor
Paul R. Fatheree
Lan Jiang
Robert Murray Mckinnell
Venkat R. Thalladi
Hao Zhang
Marta Dabros
Jerry NZEREM
Noah Benjamin
Melanie A. Kleinschek
Glenn D. CRATER
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of LT3601283T publication Critical patent/LT3601283T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
LTEPPCT/US2018/030148T 2017-05-01 2018-04-30 Kondensuoto imidazo-piperidino jak inhibitoriaus junginys LT3601283T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492574P 2017-05-01 2017-05-01
PCT/US2018/030148 WO2018204238A1 (en) 2017-05-01 2018-04-30 Fused imidazo-piperidine jak inhibitor compound

Publications (1)

Publication Number Publication Date
LT3601283T true LT3601283T (lt) 2022-02-25

Family

ID=62165730

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/030148T LT3601283T (lt) 2017-05-01 2018-04-30 Kondensuoto imidazo-piperidino jak inhibitoriaus junginys

Country Status (31)

Country Link
US (3) US10493077B2 (lt)
EP (1) EP3601283B1 (lt)
JP (1) JP7098656B2 (lt)
KR (1) KR102550225B1 (lt)
CN (1) CN110573508B (lt)
AR (1) AR111495A1 (lt)
AU (1) AU2018261593B2 (lt)
BR (1) BR112019022648A2 (lt)
CA (1) CA3056283A1 (lt)
CL (1) CL2019003086A1 (lt)
CO (1) CO2019011809A2 (lt)
CY (1) CY1125051T1 (lt)
DK (1) DK3601283T3 (lt)
EA (1) EA201992601A1 (lt)
ES (1) ES2908756T3 (lt)
HR (1) HRP20220330T1 (lt)
IL (1) IL270231B2 (lt)
LT (1) LT3601283T (lt)
MA (1) MA47970B1 (lt)
MD (1) MD3601283T2 (lt)
MX (1) MX2019012942A (lt)
NZ (1) NZ757570A (lt)
PH (1) PH12019502264A1 (lt)
PL (1) PL3601283T3 (lt)
PT (1) PT3601283T (lt)
RS (1) RS62995B1 (lt)
SG (1) SG11201908604YA (lt)
SI (1) SI3601283T1 (lt)
TW (1) TWI760486B (lt)
UA (1) UA124478C2 (lt)
WO (1) WO2018204238A1 (lt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018005446A (es) 2015-11-03 2018-08-01 Theravance Biopharma R&D Ip Llc Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria.
JP7134990B2 (ja) 2017-03-09 2022-09-12 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー 縮合イミダゾ-ピペリジンjak阻害剤
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
SG11201909019SA (en) 2017-05-01 2019-10-30 Theravance Biopharma R&D Ip Llc Methods of treatment using a jak inhibitor compound
MX2021002521A (es) 2018-09-04 2021-04-28 Theravance Biopharma R&D Ip Llc Dimetilaminoazetidinaminas como inhibidores de jak.
EP3837253B1 (en) 2018-09-04 2023-06-07 Theravance Biopharma R&D IP, LLC Process for preparing jak inhibitors and intermediates thereof
AR116114A1 (es) 2018-09-04 2021-03-31 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak
CN112955451A (zh) 2018-10-29 2021-06-11 施万生物制药研发Ip有限责任公司 作为jak抑制剂的2-氮杂双环已烷化合物
KR20210123321A (ko) * 2019-01-11 2021-10-13 내기스 파마슈티컬스 인코포레이티드 류코트리엔 합성 억제제
AU2020228799A1 (en) 2019-02-25 2021-10-07 Henan Medinno Pharmaceutical Technology Co., Ltd. JAK inhibitor compound and use thereof
CN114007621A (zh) 2019-03-05 2022-02-01 因赛特公司 用于治疗慢性肺同种异体移植物功能障碍的jak1途径抑制剂
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2021185305A1 (zh) * 2020-03-18 2021-09-23 四川海思科制药有限公司 一种吲唑衍生物及其在医药上的应用
CN111620868B (zh) * 2020-05-28 2021-08-31 爱斯特(成都)生物制药股份有限公司 一种1H-吡唑并[3,4-b]吡啶-3-甲醛的制备方法
TW202317550A (zh) * 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
CN114181055A (zh) * 2021-12-21 2022-03-15 苏州楚凯药业有限公司 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
CA2756989A1 (en) 2009-04-03 2010-10-07 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
JP5822844B2 (ja) 2009-12-21 2015-11-24 サミュメッド リミテッド ライアビリティ カンパニー 1H−ピラゾロ[3,4−b]ピリジンおよびその治療的使用
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
PT3077395T (pt) 2013-12-05 2018-01-03 Pfizer Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo e pirrolo[2,3-d]piridinilo acrilamidas
EP3143021B1 (en) 2014-05-14 2019-06-12 Pfizer Inc Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
EP3712152B1 (en) 2015-11-03 2021-01-13 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
US10556901B2 (en) 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
MX2018005446A (es) 2015-11-03 2018-08-01 Theravance Biopharma R&D Ip Llc Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria.
JP7134990B2 (ja) 2017-03-09 2022-09-12 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー 縮合イミダゾ-ピペリジンjak阻害剤
SG11201909019SA (en) 2017-05-01 2019-10-30 Theravance Biopharma R&D Ip Llc Methods of treatment using a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
SG11201909376TA (en) 2017-05-01 2019-11-28 Theravance Biopharma R&D Ip Llc Crystalline forms of a jak inhibitor compound

Also Published As

Publication number Publication date
IL270231A (lt) 2019-12-31
MA47970B1 (fr) 2022-03-31
AR111495A1 (es) 2019-07-17
NZ757570A (en) 2021-07-30
US11160810B2 (en) 2021-11-02
AU2018261593B2 (en) 2021-08-26
EA201992601A1 (ru) 2020-03-03
US10493077B2 (en) 2019-12-03
ES2908756T3 (es) 2022-05-03
EP3601283A1 (en) 2020-02-05
AU2018261593A1 (en) 2019-10-17
RS62995B1 (sr) 2022-03-31
CY1125051T1 (el) 2024-02-16
KR20190142389A (ko) 2019-12-26
CN110573508B (zh) 2022-07-05
CO2019011809A2 (es) 2020-01-17
JP7098656B2 (ja) 2022-07-11
BR112019022648A2 (pt) 2020-05-19
IL270231B2 (en) 2023-08-01
EP3601283B1 (en) 2021-12-29
US20200046719A1 (en) 2020-02-13
US20220008428A1 (en) 2022-01-13
US20180311255A1 (en) 2018-11-01
KR102550225B1 (ko) 2023-07-03
SI3601283T1 (sl) 2022-04-29
DK3601283T3 (da) 2022-04-04
SG11201908604YA (en) 2019-10-30
PT3601283T (pt) 2022-02-10
TWI760486B (zh) 2022-04-11
PL3601283T3 (pl) 2022-05-02
JP2020518581A (ja) 2020-06-25
PH12019502264A1 (en) 2020-09-21
UA124478C2 (uk) 2021-09-22
CA3056283A1 (en) 2018-11-08
CN110573508A (zh) 2019-12-13
MX2019012942A (es) 2019-12-16
MD3601283T2 (ro) 2022-05-31
CL2019003086A1 (es) 2020-01-24
HRP20220330T1 (hr) 2022-05-13
TW201841914A (zh) 2018-12-01
IL270231B1 (en) 2023-04-01
WO2018204238A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
PT3601283T (pt) Composto inibidor de jak de imidazo-piperidina fundido
ZA201905618B (en) Fused imidazo-piperidine jak inhibitors
PL3248980T3 (pl) Inhibitor jak
GB201705971D0 (en) Inhibitor compounds
GB2569389B (en) Compound
GB2569388B (en) Compound
GB201721178D0 (en) Compound
GB201721179D0 (en) Compound
GB201721172D0 (en) Compound
GB201721180D0 (en) Compound
GB201617103D0 (en) Compound
HUE057240T2 (hu) Kokristály
GB201612652D0 (en) Novel compound
GB201709565D0 (en) Compound
GB201610497D0 (en) Compound
IL268060B (en) Phenyldifluoromethyl-substituted prolinamide compound
GB201717530D0 (en) New compounds
GB201721673D0 (en) Compound
GB201721324D0 (en) Compound
GB201714049D0 (en) New compounds
GB201712289D0 (en) New compounds
GB201702729D0 (en) New compounds
GB201702732D0 (en) New compounds
GB201702735D0 (en) New compounds
GB201702725D0 (en) New compounds